Corient Private Wealth LLC trimmed its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 31.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 69,262 shares of the company's stock after selling 32,321 shares during the quarter. Corient Private Wealth LLC's holdings in Organon & Co. were worth $1,033,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in OGN. Barclays PLC raised its position in Organon & Co. by 238.0% during the third quarter. Barclays PLC now owns 119,483 shares of the company's stock valued at $2,285,000 after acquiring an additional 84,136 shares in the last quarter. Weiss Asset Management LP acquired a new position in shares of Organon & Co. during the 3rd quarter worth $32,966,000. Robeco Institutional Asset Management B.V. bought a new position in shares of Organon & Co. during the 4th quarter valued at $2,263,000. Wedmont Private Capital lifted its stake in shares of Organon & Co. by 453.4% in the 4th quarter. Wedmont Private Capital now owns 100,539 shares of the company's stock valued at $1,594,000 after purchasing an additional 82,372 shares during the last quarter. Finally, Sippican Capital Advisors boosted its holdings in Organon & Co. by 138.7% in the fourth quarter. Sippican Capital Advisors now owns 36,352 shares of the company's stock worth $542,000 after purchasing an additional 21,122 shares in the last quarter. Institutional investors own 77.43% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have weighed in on OGN. Morgan Stanley cut their target price on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a report on Friday, February 14th. TD Cowen raised Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Finally, Barclays reduced their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Organon & Co. currently has a consensus rating of "Hold" and a consensus target price of $20.80.
View Our Latest Stock Report on Organon & Co.
Organon & Co. Stock Performance
OGN stock traded down $0.05 during trading on Friday, reaching $14.52. 1,866,865 shares of the stock were exchanged, compared to its average volume of 2,538,684. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a market capitalization of $3.74 billion, a P/E ratio of 4.36, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The stock has a 50 day simple moving average of $15.33 and a 200-day simple moving average of $16.21.
Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. As a group, sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.
Organon & Co. Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.72%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is presently 33.63%.
Organon & Co. Company Profile
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
See Also
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
